Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$20.95 -1.4%	$20.01	$13.40 ▼ $25.23	$3.51B	0.64	1.97 million shs	916,956 shs
ARWR Arrowhead Pharmaceuticals	$16.78 -0.7%	$15.31	$9.57 ▼ $30.41	$2.32B	0.93	1.54 million shs	800,545 shs
ASND Ascendis Pharma A/S	$174.07 +0.6%	$167.21	$111.09 ▼ $183.00	$10.64B	0.38	498,680 shs	157,816 shs
BBIO BridgeBio Pharma	$43.71 +2.0%	$37.63	$21.72 ▼ $45.48	$8.30B	1.15	2.50 million shs	2.46 million shs
RARE Ultragenyx Pharmaceutical	$39.19 -0.7%	$36.66	$29.59 ▼ $60.37	$3.71B	0.26	837,386 shs	685,292 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-0.56%	-5.60%	-1.07%	+31.76%	+34.09%
ARWR Arrowhead Pharmaceuticals	+5.03%	+7.92%	+3.05%	+40.13%	-32.99%
ASND Ascendis Pharma A/S	+0.64%	+0.06%	-1.47%	+15.33%	+27.03%
BBIO BridgeBio Pharma	+0.12%	-3.49%	+20.78%	+25.71%	+71.94%
RARE Ultragenyx Pharmaceutical	+8.83%	+5.42%	+9.19%	+12.33%	-3.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	4.6956 of 5 stars	4.4	3.0	0.0	3.1	4.2	2.5
ARWR Arrowhead Pharmaceuticals	3.9262 of 5 stars	3.4	2.0	3.4	2.7	2.5	0.0
ASND Ascendis Pharma A/S	3.5656 of 5 stars	4.5	3.0	0.0	2.2	1.7	0.6
BBIO BridgeBio Pharma	4.704 of 5 stars	4.5	2.0	3.9	2.4	3.3	0.6
RARE Ultragenyx Pharmaceutical	4.1576 of 5 stars	3.5	1.0	3.8	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.71	Moderate Buy	$27.88	33.05% Upside
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	160.51% Upside
ASND Ascendis Pharma A/S	3.00	Buy	$220.67	26.77% Upside
BBIO BridgeBio Pharma	2.93	Moderate Buy	$58.85	34.64% Upside
RARE Ultragenyx Pharmaceutical	2.93	Moderate Buy	$87.00	122.00% Upside

Current Analyst Ratings Breakdown

Latest ARWR, ACAD, ASND, BBIO, and RARE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	ASND Ascendis Pharma A/S	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$250.00
6/30/2025	BBIO BridgeBio Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$67.00 ➝ $76.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $22.00
6/26/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$37.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/26/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
6/25/2025	BBIO BridgeBio Pharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $54.00
6/23/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$26.00 ➝ $38.00
6/20/2025	RARE Ultragenyx Pharmaceutical	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00
6/13/2025	ASND Ascendis Pharma A/S	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$215.00 ➝ $224.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	3.66	$0.69 per share	30.30	$4.40 per share	4.76
ARWR Arrowhead Pharmaceuticals	$3.55M	652.77	N/A	N/A	$1.54 per share	10.90
ASND Ascendis Pharma A/S	$393.54M	27.04	N/A	N/A	($1.88) per share	-92.59
BBIO BridgeBio Pharma	$221.90M	37.40	N/A	N/A	($7.71) per share	-5.67
RARE Ultragenyx Pharmaceutical	$560.23M	6.61	N/A	N/A	$2.76 per share	14.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	15.29	27.57	4.60	22.97%	17.46%	10.75%	8/5/2025 (Estimated)
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	18.92	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
ASND Ascendis Pharma A/S	-$409.12M	-$6.28	N/A	725.29	N/A	-93.22%	N/A	-33.29%	9/2/2025 (Estimated)
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.88	N/A	N/A	N/A	-93.04%	-186.49%	-36.81%	7/30/2025 (Estimated)

Latest ARWR, ACAD, ASND, BBIO, and RARE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/6/2025	Q1 2025	RARE Ultragenyx Pharmaceutical	-$1.54	-$1.57	-$0.03	-$1.57	$145.98 million	$139.29 million
5/1/2025	Q1 2025	ASND Ascendis Pharma A/S	-$1.56	-$1.66	-$0.10	-$1.66	$98.56 million	$123.97 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
ASND Ascendis Pharma A/S	N/A	1.04	0.71
BBIO BridgeBio Pharma	N/A	4.57	4.54
RARE Ultragenyx Pharmaceutical	N/A	2.40	2.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ARWR Arrowhead Pharmaceuticals	62.61%
ASND Ascendis Pharma A/S	N/A
BBIO BridgeBio Pharma	99.85%
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
ARWR Arrowhead Pharmaceuticals	4.30%
ASND Ascendis Pharma A/S	40.00%
BBIO BridgeBio Pharma	18.20%
RARE Ultragenyx Pharmaceutical	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	123.01 million	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
ASND Ascendis Pharma A/S	1,017	61.13 million	36.68 million	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
RARE Ultragenyx Pharmaceutical	1,310	94.54 million	89.34 million	Optionable

ARWR, ACAD, ASND, BBIO, and RARE Headlines

Recent News About These Companies

WCM Investment Management LLC Has $7.65 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

July 3 at 5:38 AM | marketbeat.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of "Moderate Buy" from Brokerages

July 3 at 2:13 AM | americanbankingnews.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of "Moderate Buy" by Analysts

July 3 at 2:11 AM | marketbeat.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 6.3% - Should You Buy?

July 2 at 1:06 PM | marketbeat.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Cross Below 50 Day Moving Average - What's Next?

July 1 at 4:19 AM | marketbeat.com

RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome

June 30 at 12:41 PM | zacks.com

Ultragenyx stock rises after FDA grants breakthrough therapy status for Angelman syndrome drug

June 27, 2025 | au.investing.com

Ultragenyx Gets FDA Designation to Expedite GTX-102 Drug Development

June 27, 2025 | marketwatch.com

Ultragenyx Pharmaceutical Inc. Receives FDA Breakthrough Therapy Designation for GTX-102 to Treat Angelman Syndrome

June 27, 2025 | quiverquant.comQ

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

June 27, 2025 | globenewswire.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Corazon (Corsee) D. Sanders Sells 2,405 Shares

June 24, 2025 | insidertrades.com

FDA Conditional Pathway Not Necessary, Rare Disease Experts Say, While Applauding Intent

June 23, 2025 | biospace.comB

Insider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Sells 2,405 Shares of Stock

June 23, 2025 | marketbeat.com

Ultragenyx Pharmaceutical Inc. Grants 48,731 Restricted Stock Units to Newly Hired Non-Executive Officers

June 20, 2025 | quiverquant.comQ

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 20, 2025 | globenewswire.com

Guggenheim Reaffirms Buy Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)

June 20, 2025 | marketbeat.com

GAMMA Investing LLC Acquires 26,625 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

June 17, 2025 | marketbeat.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Assenagon Asset Management S.A.

June 15, 2025 | marketbeat.com

Wealth Enhancement Advisory Services LLC Sells 14,701 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

June 15, 2025 | marketbeat.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 3.5% - What's Next?

June 12, 2025 | marketbeat.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by SG Americas Securities LLC

June 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR, ACAD, ASND, BBIO, and RARE Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$20.95 -0.29 (-1.37%)

Closing price 03:39 PM Eastern

Extended Trading

$20.95 0.00 (0.00%)

As of 04:20 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Arrowhead Pharmaceuticals NASDAQ:ARWR

$16.78 -0.12 (-0.71%)

Closing price 03:44 PM Eastern

Extended Trading

$16.78 0.00 (0.00%)

As of 04:20 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Ascendis Pharma A/S NASDAQ:ASND

$174.07 +0.97 (+0.56%)

Closing price 02:42 PM Eastern

Extended Trading

$174.07 0.00 (0.00%)

As of 04:01 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma NASDAQ:BBIO

$43.70 +0.88 (+2.04%)

Closing price 03:50 PM Eastern

Extended Trading

$43.12 -0.59 (-1.34%)

As of 04:20 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Ultragenyx Pharmaceutical NASDAQ:RARE

$39.19 -0.27 (-0.68%)

Closing price 03:25 PM Eastern

Extended Trading

$39.19 0.00 (0.00%)

As of 04:53 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time